glp·helper
glphelper.com/tirzepatide/texas/baytown
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide
(Mounjaro, Zepbound) in Baytown, TX

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Baytown, TX from the federal NPI registry. Ask each office whether it prescribes Mounjaro or Zepbound.[9]

  • Mounjaro: FDA-approved for type 2 diabetes.
  • Zepbound: FDA-approved for chronic weight management, and obstructive sleep apnea with obesity.
city providers
27
as of today

Same molecule (tirzepatide): Mounjaro in Baytown, Zepbound in Baytown

Other GLP-1 medicines: Ozempic in Baytown, Wegovy in Baytown, Semaglutide in Baytown

§ 02Provider directory: Texas
27 of 27 shown

Find a physician in Baytown.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Tirzepatide by Texas town, physicians per town
§ 03Getting Tirzepatide in Baytown
27 providers · Baytown, TX

How to get Tirzepatide in Baytown.

27 GLP-1 prescribers and 7 local resource types are on record for Baytown, plus 3 nearby towns in the directory.

Physicians in Baytown
27 physicians
27 physicians from the federal NPI registry in Baytown, most listed as Family Medicine (14), Internal Medicine (7) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are La Porte (18 providers), Channelview (10 providers) and Deer Park (12 providers).
Around the prescription in Baytown
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 1 trainers, 6 physiotherapists and 2 places to move are on record near Baytown.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

Bar chart of Tirzepatide dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Tirzepatide comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (brand-specific)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Baytown

Baytown, Texas has a population of 83,701 people. The adult obesity rate in Baytown is an age-adjusted estimate of 39.7%, 4.1 percentage points above the Texas state rate of 35.6%. Diagnosed diabetes reaches 14.1% of adults in Baytown. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 30.7% of adults in Baytown.

of Baytown adults have obesity
39.7%
diagnosed diabetes
14.1%
no regular physical activity
30.7%

Age-adjusted estimates for Baytown, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and hair loss
§ 05Support around Tirzepatide in Baytown
6 fitness clubs

The prescription is one part. Here is the rest, in Baytown.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Baytown, TX, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

La Porte Recreation and Fitness Center
REC CENTER
4.6 on Google · 129 reviews
1322 S Broadway St
Website
BellHouse CrossFit
FITNESS
5.0 on Google · 69 reviews
312 Bob Smith Rd
Website
Planet Fitness
FITNESS
4.3 on Google · 67 reviews
9253 Eagle Dr
Website
Sweat Club Mont Belvieu
FITNESS
5.0 on Google · 65 reviews
8830 FM 3180 Rd #301C
Website
Summit Athletics
FITNESS
4.6 on Google · 49 reviews
1806 S Battleground Rd Ste f
Website
Texas Made Boxing & Fitness
BOXING
4.6 on Google · 42 reviews
425 N 10th St
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Courtney Caesar, R.D., L.D
RD
Registered dietitian
1000 Austin St Ste D
Call 281-758-8789NPI 1003995853
Melissa Copeland
RD
Registered dietitian
14934 Lanai Dr
Call 713-906-8018NPI 1558017863
Tiffany Feathers
RD
Registered dietitian
8330 Sweet Bay Cir
Call 662-209-1372NPI 1023976107
Kayley George, RD
RD
Registered dietitian
6430 Garth Rd
Call 855-481-1149NPI 1447758412
Jennifer Gould, R.D., L.D
RD
Registered dietitian
5313 Decker Dr
Call 281-838-4477NPI 1548340490
Odalis Martinez, RD
RD
Registered dietitian
9026 Brazos Dr
Call 832-629-7088NPI 1780544056
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Tirzepatide side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Mounjaro's diabetes trials showed lower rates at the same doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 29%
mild
Lowest on Mounjaro 5 mg, highest on Zepbound 10 mg
Diarrhea
12 to 23%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Reported in Mounjaro's diabetes trials
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Tirzepatide costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Tirzepatide monthly cost by how you pay
Zepbound, pharmacy retail$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
Zepbound, LillyDirect self-pay$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Mounjaro, pharmacy retail$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Commercial insurance (weight)Often deniedZepbound is on-label but frequently requires PA
Medicare Part D$0 to $100per monthType 2 diabetes covered. Zepbound KwikPen for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Tirzepatide providers in Baytown

Physicians from the federal NPI registry. Ask each office whether it prescribes Tirzepatide.

Tirzepatide in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Tirzepatide.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Texas

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Tirzepatide is the active ingredient in two Eli Lilly brands: Mounjaro and Zepbound. No generic tirzepatide is FDA-approved in the US. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They share an active ingredient but carry different approved indications, and insurers treat them as separate products.[1]